Evaluation of blood-based proteomic biomarkers associated with response to anti-PD-1 treatment in NSCLC.

e21531Background: Immune checkpoint inhibitors have remarkably improved the natural history of patients with non-small cell lung cancer (NSCLC), with improved clinical responses and overall surviva...